RTC 119
Alternative Names: RTC-119Latest Information Update: 20 Oct 2020
At a glance
- Originator Ripple Therapeutics
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Ocular inflammation
Most Recent Events
- 20 Oct 2020 RTC 119 is available for licensing as of 20 Oct 2020. https://www.rippletherapeutics.com/
- 20 Oct 2020 Early research in Ocular inflammation in Canada (Ophthalmic) (Ripple Therapeutics pipeline, October 2020)